I have been severe in the past.Sorry if this is covered already, but I was prompted to wonder after reading that patient experience whether the experiences of severe ME/CFS patients will be part of this?
More at link:This is the third monthly report on progress with this project. You can see a list of these reports here. This month, there are updates on:
Along with this report, we’ll be updating bios and disclosures of interest at the end of the month as needed. This month, there is an update for me.
A tenth member is to be appointed by the IAG, and that has resulted in considerable debate and lobbying. Cochrane’s editor-in-chief, Karla Soares-Weiser, and I met to discuss this, and agreed to expand the IAG to add an additional position for person who has recovered from ME/CFS. Suggestions for this 11th position are welcome by August 22 to: Cochrane.IAG@gmail.com
That's exactly what I thought! Why? Without a clear diagnostic biomarker (yet) how can you be sure a recovered person had ME in the first place? It depends when they were diagnosed, by whom, and using what diagnostic criteria. As you say @Trish this review is about sorting the wheat from the chaff in terms of scientific methods.I note this:
Why? Is the obvious question.
The IAG needs poeple on it who understand things like trial review protocols, clinical trials, statistics, science, validity of outcome measures etc. Recovery from ME would be somewhere near the bottom of my list for representation. It's not about opinions about what supposedly led to an individual to recover, it's about science.
This whole process seems to me to be so tied up in 'balanced representation' of every permutation of patient experience except the one essential - a thorough understanding of clinical trials, and ensuring that valid scientific conclusions are reached in the review.
I honestly can't see any point to this. The best data we have is 5% recovery. It's not very reliable data but that's the best we have because people with neither stake nor interest in the matter keep refusing to do any better. So any such person could at best be representative of 5%, the exception. And in a fluctuating disease that is not only most commonly relapsing-remitting but also commonly misdiagnosed, this really can't tell any any more than asking what lottery winners did to win.I note this:
Why? Is the obvious question.
The IAG needs poeple on it who understand things like trial review protocols, clinical trials, statistics, science, validity of outcome measures etc. Recovery from ME would be somewhere near the bottom of my list for representation. It's not about opinions about what supposedly led to an individual to recover, it's about science.
This whole process seems to me to be so tied up in 'balanced representation' of every permutation of patient experience except the one essential - a thorough understanding of clinical trials, and ensuring that valid scientific conclusions are reached in the review.
The best data we have is 5% recovery. It's not very reliable data but that's the best we have because people with neither stake nor interest in the matter keep refusing to do any better. So any such person could at best be representative of 5%, the exception. And in a fluctuating disease that is not only most commonly relapsing-remitting but also commonly misdiagnosed, this really can't tell any any more than asking what lottery winners did to win.
The 5% figure came from a review (https://pubmed.ncbi.nlm.nih.gov/15699087/) that mostly relied on people that had been sick for around 5 years or longer, and on studies that had relatively short follow ups (most with 2 years or less). For people sick for less than 5 or 2 years the chance of recover seems to be substantially better, and it also seems to be better for people that get sick when youngI honestly can't see any point to this. The best data we have is 5% recovery. It's not very reliable data but that's the best we have because people with neither stake nor interest in the matter keep refusing to do any better. So any such person could at best be representative of 5%, the exception. And in a fluctuating disease that is not only most commonly relapsing-remitting but also commonly misdiagnosed, this really can't tell any any more than asking what lottery winners did to win.
It's possible to find such a person. But to represent the 5% exception, seems either pointless or perilous. One clear thing that Long Covid has especially emphasized is how varied the illness presentation is, not only between people but in time. So much that it requires massive cohorts simply to glimpse the most common patterns. I can't see how 1 person's account can serve any purpose. It also depends on where we place the cutoff because the overall symptomology is too similar whether someone is ill for a lifetime or 6 months.
As usual, there is an XKCD for that:
![]()
Surely not. I may not have agreed with some of the appointments, but I would trust Hilda and the rest of the IAG not to make such a ridiculous misjudgement.I hate to say it but this seems like a sneaky way to get the Lightning Process into the mix.
I'm not sure that it is much more ridiculous than deciding that 'recovery from ME/CFS' is an appropriate qualification for assessing the scientific quality of the evidence for GET.Surely not. I may not have agreed with some of the appointments, but I would trust Hilda and the rest of the IAG not to make such a ridiculous misjudgement.
Thanks for the latest progress report, @Hilda Bastian. Like others, I’m puzzled why you and Karla Soares-Weiser decided to add “a person who has recovered from ME/CFS” to the IAG. Please can you explain your reasoning behind this decision?At this point, nine members of the IAG have been appointed including me – you can see their bios and disclosures of interest here. A tenth member is to be appointed by the IAG, and that has resulted in considerable debate and lobbying. Cochrane’s editor-in-chief, Karla Soares-Weiser, and I met to discuss this, and agreed to expand the IAG to add an additional position for person who has recovered from ME/CFS. Suggestions for this 11th position are welcome by August 22 to: Cochrane.IAG@gmail.com
I agree that this recovery business makes a mockery of the whole exercise. Would one have someone who had recovered with homeopathy on a homeopathy review? Or someone who had recovered without homeopathy?